Technical Analysis for TVGN - Tevogen Bio Holdings Inc.

Grade Last Price % Change Price Change
D 2.37 -6.32% -0.16
TVGN closed down 6.32 percent on Friday, November 1, 2024, on 22 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong Down Up Down

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Wide Bands Range Expansion 0.00%
Crossed Above 200 DMA Bullish -6.32%
Hammer Candlestick Bullish -6.32%
180 Bullish Setup Bullish Swing Setup -6.32%
Calm After Storm Range Contraction -6.32%
Doji - Bullish? Reversal -6.32%
Wide Bands Range Expansion -6.32%
Overbought Stochastic Strength -6.32%
Fell Below 200 DMA Bearish -3.66%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 19 hours ago
10 DMA Support about 21 hours ago
200 DMA Support about 21 hours ago
Bullish 180 Entry about 21 hours ago
Hammer Candlestick Entry about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Tevogen Bio Holdings Inc. Description

Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents and twelve pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Artificial Intelligence Immunotherapy Infectious Diseases Virotherapy Drug Development Neurological Disorders

Is TVGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Date Title
Oct 31 Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs
Oct 29 Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company
Oct 29 Tevogen Bio Signs Letter of Intent With CD8 Technology to Build Up to a $50 Million R&D and Manufacturing Facility; No Impact on Shareholder Equity
Oct 28 Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Oct 25 Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas
Oct 23 Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating drug Development
Oct 22 Tevogen Bio To Provide Timelines Associated with Recently Announced Revenue Forecast and Updates on Operational Readiness This Week
Oct 21 Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
Oct 21 Tevogen Bio Provides Clarity on CSO Share Sales to Satisfy Tax Obligations, Expects Additional Forecast and Progress Updates in the Coming Days
Oct 19 Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days
See more TVGN news...

Indicators

Indicator Value
52 Week High 21.09
52 Week Low 0.2578
Average Volume 18,739,163
200-Day Moving Average 2.38
50-Day Moving Average 0.91
20-Day Moving Average 1.62
10-Day Moving Average 2.42
Average True Range 0.43
RSI (14) 65.28
ADX 62.12
+DI 29.98
-DI 6.96
Chandelier Exit (Long, 3 ATRs) 1.81
Chandelier Exit (Short, 3 ATRs) 1.54
Upper Bollinger Bands 3.47
Lower Bollinger Band -0.23
Percent B (%b) 0.7
BandWidth 228.99
MACD Line 0.55
MACD Signal Line 0.48
MACD Histogram 0.0627
Fundamentals Value
Market Cap 35.4 Million
Num Shares 14.9 Million
EPS 0.09
Price-to-Earnings (P/E) Ratio 26.33
Price-to-Sales 0.00
Price-to-Book 6.87
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.86
Resistance 3 (R3) 2.89 2.76 2.78
Resistance 2 (R2) 2.76 2.64 2.75 2.75
Resistance 1 (R1) 2.57 2.56 2.50 2.53 2.72
Pivot Point 2.44 2.44 2.41 2.42 2.44
Support 1 (S1) 2.24 2.31 2.18 2.21 2.02
Support 2 (S2) 2.11 2.24 2.10 1.99
Support 3 (S3) 1.92 2.11 1.96
Support 4 (S4) 1.88